全文获取类型
收费全文 | 3607篇 |
免费 | 417篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 26篇 |
儿科学 | 105篇 |
妇产科学 | 80篇 |
基础医学 | 516篇 |
口腔科学 | 162篇 |
临床医学 | 372篇 |
内科学 | 772篇 |
皮肤病学 | 49篇 |
神经病学 | 294篇 |
特种医学 | 85篇 |
外国民族医学 | 5篇 |
外科学 | 395篇 |
综合类 | 74篇 |
一般理论 | 2篇 |
预防医学 | 489篇 |
眼科学 | 163篇 |
药学 | 259篇 |
中国医学 | 5篇 |
肿瘤学 | 180篇 |
出版年
2023年 | 34篇 |
2021年 | 53篇 |
2020年 | 32篇 |
2019年 | 49篇 |
2018年 | 62篇 |
2017年 | 41篇 |
2016年 | 67篇 |
2015年 | 67篇 |
2014年 | 96篇 |
2013年 | 172篇 |
2012年 | 173篇 |
2011年 | 180篇 |
2010年 | 106篇 |
2009年 | 89篇 |
2008年 | 158篇 |
2007年 | 195篇 |
2006年 | 203篇 |
2005年 | 206篇 |
2004年 | 195篇 |
2003年 | 189篇 |
2002年 | 164篇 |
2001年 | 43篇 |
2000年 | 37篇 |
1999年 | 50篇 |
1998年 | 44篇 |
1997年 | 26篇 |
1995年 | 30篇 |
1994年 | 30篇 |
1993年 | 48篇 |
1992年 | 33篇 |
1991年 | 33篇 |
1990年 | 42篇 |
1989年 | 40篇 |
1988年 | 34篇 |
1987年 | 38篇 |
1986年 | 34篇 |
1985年 | 45篇 |
1984年 | 38篇 |
1983年 | 34篇 |
1982年 | 47篇 |
1981年 | 44篇 |
1980年 | 44篇 |
1979年 | 32篇 |
1978年 | 45篇 |
1977年 | 51篇 |
1976年 | 39篇 |
1975年 | 30篇 |
1974年 | 24篇 |
1973年 | 23篇 |
1969年 | 28篇 |
排序方式: 共有4033条查询结果,搜索用时 171 毫秒
1.
2.
BackgroundResearchers are working at unprecedented speed to develop a SARS-CoV-2 vaccine. We aimed to assess the value of a hypothetical vaccine and its potential public health impact when prioritization is required due to supply constraints.MethodsA Markov cohort model was used to estimate COVID-19 related direct medical costs and deaths in the United States (US), with and without implementation of a 60% efficacious vaccine. To prioritize the vaccine under constrained supply, the population was divided into tiers based on age; risk and age; and occupation and age; and outcomes were compared across one year under various supply assumptions. The incremental cost per quality-adjusted life-year (QALY) gained versus no vaccine was calculated for the entire adult population and for each tier in the three prioritization schemes.ResultsThe incremental cost per QALY gained for the US adult population was $8,200 versus no vaccination. For the tiers at highest risk of complications from COVID-19, such as those ages 65 years and older, vaccination was cost-saving compared to no vaccination. The cost per QALY gained increased to over $94,000 for those with a low risk of hospitalization and death following infection. Results were most sensitive to infection incidence, vaccine price, the cost of treating COVID-19, and vaccine efficacy. Under the most optimistic supply scenario, the hypothetical vaccine may prevent 31% of expected deaths. As supply becomes more constrained, only 23% of deaths may be prevented. In lower supply scenarios, prioritization becomes more important to maximize the number of deaths prevented.ConclusionsA COVID-19 vaccine is predicted to be good value for money (cost per QALY gained <$50,000). The speed at which an effective vaccine can be made available will determine how much morbidity and mortality may be prevented in the US. 相似文献
3.
Stefano Cascinu György Bodoky Kei Muro Eric Van Cutsem Sang Cheul Oh Gunnar Folprecht Sumitra Ananda Gustavo Girotto Zev A. Wainberg Maria Luisa Limon Miron Jaffer Ajani Ran Wei Astra M. Liepa Roberto Carlesi Michael Emig Atsushi Ohtsu 《The oncologist》2021,26(3):e414-e424
BackgroundIn the intent‐to‐treat (ITT) population of the RAINBOW study, objective response rate (ORR) was 28% and 16% in the ramucirumab and control arms, respectively. To further characterize tumor response, we present details on timing and extent of tumor shrinkage, as well as associations with symptom palliation.Materials and MethodsTumor response was assessed with RECIST v1.1, and quality of life (QoL) was assessed with the European Organization for Research and Treatment of Cancer Quality‐of‐Life Questionnaire‐Core 30 (EORTC QLQ‐C30) v3.0. Prespecified and post hoc analyses were conducted in the ITT population, patients with measurable disease, or responders, and included best overall response (BOR), ORR, disease control rate (DCR), duration of response, time to response (TtR), change in tumor size, and associations of QoL with tumor shrinkage and BOR.ResultsIn both treatment arms, median TtR was 1.5 months. Responses were more durable in the ramucirumab versus control arm (median 4.4 vs. 2.8 months). In patients with measurable disease (78% of ITT), ORR was 36% versus 20%; DCR was 81% versus 61% in the ramucirumab versus control arms. Waterfall plots demonstrated more tumor shrinkage in the ramucirumab versus control arm. Regardless of treatment, tumor response and stable disease were associated with improved or stable QoL, with more tumor shrinkage associated with greater symptom palliation.ConclusionTreatment with ramucirumab plus paclitaxel yielded the highest ORR reported to date for patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma. Additional details demonstrate robustness of tumor response results. The extent of tumor shrinkage is directly associated with symptom palliation and should be considered when evaluating patient needs and treatment selection. Clinical trial identification number. .Implications for PracticeRamucirumab plus paclitaxel is a recognized standard of care as it improves survival for patients with advanced gastric or gastroesophageal junction adenocarcinoma who have been previously treated with recommended first‐line therapy. These additional data on tumor response demonstrate a positive association between tumor shrinkage and symptom palliation in a patient population that is often symptomatic. These observations included patients with nonmeasurable disease, a group of patients often underrepresented in clinical trials. This knowledge can inform treatment decisions, which align individual patient characteristics and needs with demonstrated benefits. NCT01170663相似文献
4.
Osric A. Forrest Daniel M. Chopyk Yael Gernez Milton R. Brown Carol K. Conrad Richard B. Moss Vin Tangpricha Limin Peng Rabindra Tirouvanziam 《Journal of cystic fibrosis》2019,18(1):64-70
Background
Resistin is an immunometabolic mediator that is elevated in several inflammatory disorders. A ligand for Toll-like receptor 4, resistin modulates the recruitment and activation of myeloid cells, notably neutrophils. Neutrophils are major drivers of cystic fibrosis (CF) lung disease, in part due to the release of human neutrophil elastase- and myeloperoxidase-rich primary granules, leading to tissue damage. Here we assessed the relationship of resistin to CF lung disease.Methods
Resistin levels were measured in plasma and sputum from three retrospective CF cohorts spanning a wide range of disease. We also assessed the ability of neutrophils to secrete resistin upon activation in vitro. Finally, we constructed a multivariate model assessing the relationship between resistin levels and lung function.Results
Plasma resistin levels were only marginally higher in CF than in healthy control subjects. By contrast, sputum resistin levels were very high in CF, reaching 50–100 fold higher levels than in plasma. Among CF patients, higher plasma resistin levels were associated with allergic bronchopulmonary aspergillosis, and higher sputum resistin levels were associated with CF-related diabetes. Mechanistically, in vitro release of neutrophil primary granules was concomitant with resistin secretion. Overall, sputum resistin levels were negatively correlated with CF lung function, independently of other variables (age, sex, and genotype).Conclusions
Our data establish relationships between resistin levels in the plasma and sputum of CF patients that correlate with disease status, and identify resistin as a novel mechanistic link between neutrophilic inflammation and lung disease in CF. 相似文献5.
Edson Donizetti Verri Gabriel Pdua da Silva Evandro Marianetti Fioco Nayara Soares da Silva Saulo Csar Valin Fabrin Cesar Augusto Bueno Zanella Camila Roberta Garrefa Milton Faria Júnior Selma Sissere Jaime Eduardo Cecilio Hallak Marcelo Palinkas Thais Cristina Chaves Simone Cecilio Hallak Regalo 《Journal of oral rehabilitation》2019,46(10):912-919
6.
7.
8.
9.
10.
AbstractAlcohol hangover syndrome (AHS) is a highly heterogenous state encompassing a range of physiological and psychological symptoms. The syndrome is experienced regularly among alcohol consumers and remains poorly understood. The present study sought to gain insight into whether certain emotions were tied to AHS and how these emotions were experienced. Twenty participants took part, 14 female and 6 male, aged 21 to 39 years. Inductive thematic analysis of semi structured interview data produced four themes; ‘The Tyranny of the Shoulds’, ‘Bias and the Persistence of Memory’, ‘Staring into the Void’, and ‘Emotive behavioral response’. The four themes demonstrate the complexity of emotional experiences associated with AHS and account for concurrent constructs including cognition, mood, and behavior. Guilt, shame, dread, anger, and regret were all commonly experienced, with rumination, negative interpretation bias, nostalgia, self-flagellation, isolation and camaraderie being essential in how these emotions were described by participants. The study adds greater understanding of the diversity of emotions that can be experienced during AHS, with important implications for the wellbeing of those who suffer most from the state. It is suggested that self-help techniques targeting cognitions could be explored to help alleviate aspects of the negative emotions experienced. 相似文献